Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

(2020) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours

(2020) Fei Xu et al.   Cell and Bioscience

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

(2020) Charles Pottier et al.   Cancers

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

(2019) Martin Schuler et al.   LUNG CANCER

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis

(2019) Hongwei Zhang et al.   PLoS One

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

(2019) Nobuyuki Yamamoto et al.   ADVANCES IN THERAPY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations

(2018) Tony S. Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer stem cells: A brief review of current status

(2018) Alican Kuşoğlu et al.   GENE

The PI3K/AKT pathway in obesity and type 2 diabetes

(2018) Xingjun Huang et al.   International Journal of Biological Sciences

Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing

(2018) Shinji Kohsaka et al.   Future Oncology

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

(2018) Tatsuya Nagano et al.   Cells

Tumor Evolution as a Therapeutic Target

(2017) Nabil Amirouchene-Angelozzi et al.   Cancer Discovery

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1–TUFM protein complex

(2016) Y Lei et al.   ONCOGENE

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

(2016) Arpita Desai et al.   Cancer Biology & Medicine

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib

(2015) Vera Hirsh   BIODRUGS

The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy

(2015) Zutao Yu et al.   Future Medicinal Chemistry

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

(2015) William D. Travis et al.   Journal of Thoracic Oncology

MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms

(2015) Pui-Kei Wu et al.   SEMINARS IN ONCOLOGY

Non-small-cell lung cancer

(2015) Cesare Gridelli et al.   Nature Reviews Disease Primers

Radon, Smoking, and Lung Cancer: The Need to Refocus Radon Control Policy

(2013) Paula M. Lantz et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Genetic alterations defining NSCLC subtypes and their therapeutic implications

(2013) Larissa A. Pikor et al.   LUNG CANCER

Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints

(2013) Ran Friedman   PLoS One

PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses

(2013) Carol Dangelmaier et al.   THROMBOSIS AND HAEMOSTASIS

MAP Kinase Pathways

(2012) D. K. Morrison   Cold Spring Harbor Perspectives in Biology

FoxO transcription factors; Regulation by AKT and 14-3-3 proteins

(2011) Guri Tzivion et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

ERK dimers and scaffold proteins: Unexpected partners for a forgotten (cytoplasmic) task

(2011) Berta Casar et al.   CELL CYCLE

Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma

(2011) P. Broet et al.   CLINICAL CANCER RESEARCH

Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis

(2011) X. Tang et al.   CLINICAL CANCER RESEARCH

Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein Kinase (MAPK) and Phosphatidylinositol-3-kinase (PI3K)/AKT pathways

(2011) Jun-ichi Hanai et al.   JOURNAL OF CELLULAR PHYSIOLOGY

A Negative Regulatory Pathway of GLUT4 Trafficking in Adipocyte: New Function of RIP140 in the Cytoplasm via AS160

(2009) Ping-Chih Ho et al.   Cell Metabolism

Oncogenic Activating Mutations Are Associated with Local Copy Gain

(2009) B. Modrek et al.   MOLECULAR CANCER RESEARCH

Review: Targeted therapies in small cell lung cancer: a review

(2009) Aidalena Z. Abidin et al.   Therapeutic Advances in Medical Oncology

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

(2008) Amit Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of Glucose Transporter 4 Translocation by the Rab Guanosine Triphosphatase-Activating Protein AS160/TBC1D4: Role of Phosphorylation and Membrane Association

(2008) Jacqueline Stöckli et al.   MOLECULAR ENDOCRINOLOGY

Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway

(2008) O Bermudez et al.   ONCOGENE

Disruption of the EGFR E884–R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity

(2008) Z Tang et al.   ONCOGENE